Professor of Medicine
Duke University Medical Center
Durham, NC, United States
Dr. Fowler is Florence McAlister Distinguished Professor of Medicine and Professor of Molecular Genetics and Microbiology in the Division of Infectious Diseases at Duke University. His research in Staphylococcus aureus and other drug resistant bacteria has led to over two decades of continuous NIH funding as PI. He is the Founding Contact PI of the Antibacterial Resistance Leadership Group (ARLG), a grant with a total value of over $160 million to design and execute clinical research in antibacterial resistance. Under Dr Fowler’s leadership, the ARLG went from creation in 2013 to over 40 studies involving >21,000 patients from >130 sites in 12 countries producing >120 publications and 2 FDA approvals. He created the S. aureus Bacteremia Group, co-founded the International Collaboration on Endocarditis, and was lead author on the Phase 3 trial that led to the FDA indication of daptomycin for MRSA bacteremia. He received the Clinical Research Achievement Award for publishing one of the top ten clinical research papers in the US in 2012, and the Translational Research Mentoring Award from Duke School of Medicine in 2018. He has over 330 peer-reviewed publications with over 31,000 citations.
Disclosure(s): Affinergy: Advisor/Consultant; ArcBio: Stocks/Bonds (Private Company); Armata: Advisor/Consultant; Astra Zeneca: Advisor/Consultant, Grant/Research Support; Basilea: Advisor/Consultant, Grant/Research Support; ContraFect: Advisor/Consultant, Grant/Research Support; Debiopharm: Advisor/Consultant; Destiny: Advisor/Consultant; EDE: Grant/Research Support; Genentech: Advisor/Consultant, Grant/Research Support; GSK: Advisor/Consultant; Janssen: Advisor/Consultant; Karius: Grant/Research Support; MedImmune: Grant/Research Support; Merck: Grant/Research Support; sepsis diagnostics: Patent pending; UptoDate: Royalties; Valanbuio: Stocks/Bonds (Private Company), Stocks/Bonds (Private Company)
Thursday, October 17, 2024
11:00 AM – 11:15 AM US PT